Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,064 Hematology
clinical trials

Polycythemia Vera Clinical Trial
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Status: Enrolling, Phase II
Updated: 12/31/1969
Peter MacCallum Cancer Centre; Department of Haematology
mi
from
Melbourne,
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling, Phase
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling, Phase
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Plasma Cell Myeloma Clinical Trial
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Relapsed or Refractory Multiple Myeloma Clinical Trial
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Research Site
mi
from
Clayton,
Click here to add this to my saved trials
Relapsed or Refractory Multiple Myeloma Clinical Trial
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Relapsed or Refractory Multiple Myeloma Clinical Trial
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Relapsed/Refractory Multiple Myeloma Clinical Trial
A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Relapsed/Refractory Multiple Myeloma Clinical Trial
A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)
Status: Enrolling, Phase IV
Updated: 12/31/1969
Karmanos Cancer Institute ( Site 0001)
mi
from
Bloomfield Hills, MI
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)
Status: Enrolling, Phase IV
Updated: 12/31/1969
Millennium Physicians Association
mi
from
Shenandoah, TX
Click here to add this to my saved trials
Hematologic Malignancies Clinical Trial
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Status: Enrolling, Phase I
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Insitute
mi
from
Columbus, OH
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Status: Enrolling, Phase
Updated: 4/10/2018
University of Toronto, Mount Sinai Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cellectar Biosciences site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Status: Enrolling, Phase III
Updated: 12/31/1969
Catholic Health Institute St. Francis
mi
from
Grand Island, NE
Click here to add this to my saved trials
Amyloidosis Clinical Trial
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Status: Enrolling, Phase III
Updated: 12/31/1969
Box Hill Hospital
mi
from
Box Hill,
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Johns Hopkins All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
San Jorge Children's Hospital
mi
from
San Juan,
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Norton Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Oncology, Orthopedics / Podiatry Clinical Trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status: Enrolling, Phase IV
Updated: 12/31/1969
Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente Downey Medical Center
mi
from
Downey, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Florida Health Science Center ?? Gainesville
mi
from
Gainesville, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
NYU Winthrop Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Acute Myeloid Leukemia (AML) Clinical Trial
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Norton Cancer Institute /ID# 158998
mi
from
Louisville, KY
Click here to add this to my saved trials
Acute Myeloid Leukemia (AML) Clinical Trial
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Pittsburgh Medical Center /ID# 158997
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
Rcca Md, Llc
mi
from
Bethesda, MD
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
VA North texas Health Care sytem,Dallas VA Medical Center div. Hematology Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
Mercy Research
mi
from
Springfield, MO
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
Arizona Oncology Associates- East Valley Cancer Center
mi
from
Tempe, AZ
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Endocrinology, Hematology Clinical Trial
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
Status: Enrolling, Phase II
Updated: 12/31/1969
Spruce Biosciences Clinical Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Relapsed and/or Refractory Multiple Myeloma Clinical Trial
An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Icon Cancer Care South Brisbane
mi
from
South Brisbane,
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Status: Enrolling, Phase
Updated: 12/31/1969
Children's Rehabilitation Services/ University of South Alabama
mi
from
Mobile, AL
Click here to add this to my saved trials
Acute Myeloid Leukaemia Clinical Trial
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Patients.
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Status: Enrolling, Phase III
Updated: 12/31/1969
Incyte Investigative Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Status: Enrolling, Phase III
Updated: 12/31/1969
Incyte Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Status: Enrolling, Phase III
Updated: 12/31/1969
Incyte Investigative Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Status: Enrolling, Phase III
Updated: 12/31/1969
Incyte Investigative Site
mi
from
Maywood, IL
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Status: Enrolling, Phase III
Updated: 12/31/1969
Incyte Investigative Site
mi
from
New Haven, CT
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Status: Enrolling, Phase III
Updated: 12/31/1969
Incyte Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Status: Enrolling, Phase III
Updated: 12/31/1969
Incyte Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
AML, Adult Clinical Trial
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Johns Hopkins Hospital - Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
Northwell Health
mi
from
Lake Success, NY
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures
Status: Enrolling, Phase IV
Updated: 12/31/1969
Johns Hopkins All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Northside
mi
from
Atlanta, GA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Massachusetts
mi
from
Worcester, MA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Status: Enrolling, Phase II
Updated: 12/31/1969
CHRU de Brest - Hopital Morvan
mi
from
Brest Cedex,
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Icon Cancer Care Wesley
mi
from
Auchenflower,
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Texas Oncology (West 38) - USOR
mi
from
Austin, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
SCRI Florida Cancer Specialists North
mi
from
Brandon, FL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Rocky Mountain Cancer Centers (Colorado Springs) - USOR
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
SCRI Tennessee Oncology - Dickson
mi
from
Dickson, TN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Rocky Mountain Cancer Centers (Lone Tree) - USOR
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
SCRI Tennessee Oncology Nashville
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
SCRI Tennessee Oncology - St Thomas West
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
SCRI Tennessee Oncology - Southern Hills
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Rocky Mountain Cancer Centers (Parker) - USOR
mi
from
Parker, CO
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.
mi
from
Riverside, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Arizona Oncology Associates (Wilmont HOPE) - USOR
mi
from
Tucson, AZ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Texas Oncology (Tyler) - USOR
mi
from
Tyler, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Wytheville, VA
Click here to add this to my saved trials
Chronic Phase Chronic Myeloid Leukemia Clinical Trial
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Status: Enrolling, Phase
Updated: 12/31/1969
ARH Hazard
mi
from
Hazard, KY
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
Status: Enrolling, Phase III
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Hematology
mi
from
Chicago, IL
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
Status: Enrolling, Phase III
Updated: 12/31/1969
Blood Research Institute at Blood Center of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
Status: Enrolling, Phase III
Updated: 12/31/1969
UC Davis Hemophilia Treatment Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder Clinical Trial
Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Florida (Adults and Pediatrics)
mi
from
Gainesville, FL
Click here to add this to my saved trials
Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder Clinical Trial
Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Pennsylvania (Adults only)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hereditary Hemochromatosis Clinical Trial
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Hereditary Hemochromatosis Clinical Trial
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
Hereditary Hemochromatosis Clinical Trial
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Hereditary Hemochromatosis Clinical Trial
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Amyloidosis, Hereditary Clinical Trial
ATTR Expanded Access Program (EAP) by Ionis
Status: Enrolling, Phase
Updated: 12/31/1969
SC3 Research - Pasadena
mi
from
Pasadena, CA
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases, Nephrology / Urology Clinical Trial
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Florida Congenital Heart Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Immunology / Infectious Diseases, Nephrology / Urology Clinical Trial
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Enrolling, Phase III
Updated: 12/31/1969
Johns Hopkins All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Baylor Scott & White
mi
from
Dallas, TX
Click here to add this to my saved trials
Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder Clinical Trial
Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab
Status: Enrolling, Phase III
Updated: 12/31/1969
Washington University School of Medicine (Adults only)
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Robert Wood Johnson Medical School/RWJ University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Status: Enrolling, Phase II
Updated: 12/31/1969
Harvard Medical School -- Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Clinical Trial
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With wAIHA or CAD
Status: Enrolling, Phase II
Updated: 12/31/1969
New York Cancer and Blood Specialists
mi
from
Bronx, NY
Click here to add this to my saved trials
Warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Clinical Trial
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With wAIHA or CAD
Status: Enrolling, Phase II
Updated: 12/31/1969
Apellis Clinical Site
mi
from
Whittier, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Status: Enrolling, Phase
Updated: 12/31/1969
UConn Dental Medicine
mi
from
Farmington, CT
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Status: Enrolling, Phase
Updated: 12/31/1969
Sacramento ENT
mi
from
Roseville, CA
Click here to add this to my saved trials
Chronic Graft Versus Host Disease cGVHD Clinical Trial
Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Hematology, Orthopedics / Podiatry Clinical Trial
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
Status: Enrolling, Phase II
Updated: 12/31/1969
Blood and Marrow Transplant Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Fabry Disease Clinical Trial
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Minnesota - Pediatric Gene Therapy
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Relapsed/Refractory Multiple Myeloma Clinical Trial
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Relapsed/Refractory Multiple Myeloma Clinical Trial
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Research Site
mi
from
Melbourne,
Click here to add this to my saved trials
Relapsed/Refractory Multiple Myeloma Clinical Trial
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Short Course Daratumumab in Patients With Multiple Myeloma
Status: Enrolling, Phase II
Updated: 12/31/1969
Memoral Sloan Kettering Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials